Bristol Myers Squibb and Cellares form a $380M supply agreement for CAR T cell therapy manufacturing.

Bristol Myers Squibb (BMY) and Cellares announce a $380M worldwide capacity reservation and supply agreement for CAR T cell therapies manufacturing. Cellares will optimize, automate, and tech-transfer select BMY therapies onto its Cell Shuttle platform, with dedicated systems in the U.S., EU, and Japan for exclusive use by BMY. The deal aims to bring the promise of cell therapy to more patients, faster.